Written by: ScanSkinAI Editorial Team
Medically reviewed by: Dr. Celina Kazumi Iwasa, MD — GMC-Registered Dermatologist
Last medically reviewed: June 2026 · Last updated: June 2026
Evidence standard: NHS · NICE · Cancer Research UK · British Association of Dermatologists · peer-reviewed dermatology literature.
AI Skin Cancer Screening API for Insurers and Digital Health Platforms
Embed ScanSkinAI into your insurer, employee-benefits, telemedicine or healthcare platform through REST API, white-label widget, SSO or direct access.
- ISO 27001
- ISO 13485
- UKCA Class I
- 95.3% clinical concordance
Who ScanSkinAI Is Built For
Insurers and Brokers
Add AI-supported skin screening to member benefits, wellness programmes and insurance platforms.
Telemedicine and Digital Health
Use AI-supported assessment before consultations and route suitable cases into professional review.
Clinics, Pharmacies and Healthcare Providers
Add image assessment, monitoring and structured reports to existing healthcare workflows.
Large Employers
Provide private employee skin screening with enterprise onboarding, SSO and aggregated engagement reporting.
AI Skin Screening Platform
The core product partners embed and resell — AI-supported skin assessment with structured outputs and triage guidance.
- AI-supported assessment of 80+ skin conditions
- Mole and lesion screening
- ABCDE feature analysis
- Multi-lesion detection
- Change-over-time tracking
- Four-level triage guidance
- Structured reports
- Optional dermatologist review
Additional Health APIs
Partners can also access optional oral health, cardiovascular risk and CBC cancer-risk tools to extend their preventive-health proposition alongside skin screening.
Integration Options
Four production-ready ways to deploy AI skin cancer screening for insurers and digital health partners.
Direct platform access
- Development effort
- Lowest
- Typical use case
- Pilots, employer roll-outs, brokers signposting members to a hosted ScanSkinAI experience.
- Branding level
- ScanSkinAI-branded
- Deployment route
- Hosted URL or co-branded landing page
Embeddable web widget
- Development effort
- Low
- Typical use case
- Insurer or telemedicine portals adding a drop-in scan flow inside an existing logged-in area.
- Branding level
- White-label with partner theme
- Deployment route
- Script tag or iframe embed
SSO integration
- Development effort
- Medium
- Typical use case
- Enterprises and large employers connecting member identity through SAML 2.0 or OAuth 2.0.
- Branding level
- Co-branded or fully white-label
- Deployment route
- Identity-federated access into ScanSkinAI or the embedded widget
REST API and SDK
- Development effort
- Higher
- Typical use case
- Insurtechs and digital health platforms building native journeys around ScanSkinAI outputs.
- Branding level
- Fully white-label inside partner UI
- Deployment route
- Documented REST API with mobile SDK and sandbox
Together, these options make AI skin cancer screening for insurers, brokers, telemedicine and digital health platforms straightforward to deploy at the level of branding and engineering effort that fits each partner.
Optional Dermatologist Review
Partners can offer an optional written review by a GMC-registered dermatologist alongside AI screening. Suitable for cases the AI flags as higher priority or where the partner wants a clinician-confirmed opinion before signposting members to in-person care.
Learn about dermatologist review →Clinical Validation: Independent Dermatologist Audit Results
100-case audit by an independent dermatologist under a locked protocol. Blinded review of real-world production scans — not lab conditions.
Document ID: IVY-CLIN-001 · Effective Date: March 10, 2026 · Protocol: IVY-CLIN-PROTO-001
Clinical concordance
Independent dermatologist audit · 100 real-world production scans · blinded review under locked protocol.
Three-Tier Performance
ISO 27001:2022
Information security management certified. All health data encrypted, access-controlled, and audited to international standards.
ISO 13485
Quality management certified. Consistent, reliable screening results that meet rigorous health technology standards.
Why does clinical validation matter for your business?
ScanSkinAI's models are independently audited — 95.3% clinical concordance means fewer false positives, better triage, and lower costs.
ScanSkinAI is a wellness screening tool. It does not replace clinical assessment by a qualified dermatologist.
Example Integration Workflows
Illustrative examples of how partners can deploy ScanSkinAI. These describe possible workflows, not measured customer results.
Example workflow
Insurer member benefit
Members sign into the insurer portal, launch the embedded ScanSkinAI widget, complete a skin check and receive structured triage guidance. Higher-priority cases are signposted to in-network clinicians.
Example workflow
Telemedicine pre-consultation
Patients booking a dermatology consultation complete an AI-supported skin assessment first. The structured report is shared with the clinician to inform the video consultation.
Example workflow
Employer wellbeing programme
Employees access ScanSkinAI through SSO from the benefits hub. The employer receives aggregated, de-identified engagement reporting only — no individual results.
Security and Data Protection
- ISO 27001:2022 information security management.
- ISO 13485 medical device quality management.
- UKCA Class I medical device.
- Encryption in transit and at rest, role-based access and audit trails.
- NDA, DPA and data-residency configurations available for partner security reviews.
Frequently Asked Questions
Platforms that already own a customer relationship and want to add clinically validated AI skin screening under their own brand — insurtechs, telemedicine platforms, dermatology clinics, online pharmacies, health & beauty apps, laboratory networks and other healthtech providers. Partners then resell or deliver ScanSkinAI to their insurers, employers, clinics and end-users.
Four production-ready paths: REST API and mobile SDK for full embedding, a drop-in white-label web widget, SSO via SAML 2.0 and OAuth 2.0, and an MCP server to plug ScanSkinAI into ChatGPT, Claude or custom AI agents. A sandbox and developer portal are provided.
A unified plan covering enhanced skin cancer screening (80+ conditions with ABCDE auto-flagging and mole-change tracking), Ivy AI Oral Check, Heart Risk Check and 6-Cancer Risk Screening (lung, breast, colorectal, prostate, skin, cervical). Once a user signs in, every check is unlocked.
Derm Review is the only feature billed per use. When the AI flags a lesion, the user pays for a board-certified dermatologist to review it and return a written opinion — Express in 8 hours or Standard in 48 hours. Partners can mark it up or bundle it into their own tiers.
Yes. Approved partners receive tiered revenue share on every plan or review sold through their integration, plus co-marketing, joint case studies and a listing in our partner directory. Specific commercials are agreed in the partnership contract.
White-label web widget and SSO deployments typically go live in days. Full REST API and mobile SDK integrations usually take 4–8 weeks depending on scope. Sandbox, OpenAPI spec and integration support are provided from day one.
Yes. ScanSkinAI holds ISO 27001:2022, ISO 13485 and UKCA Class I. A 100-case independent dermatologist audit achieved 95.3% clinically acceptable accuracy, and the AI is validated on Fitzpatrick skin types I–VI.
All health data is encrypted at rest and in transit, with role-based access controls and full audit trails. NDA, DPA and data-residency configurations are available so partners can pass enterprise security reviews and meet GDPR / HIPAA-aligned obligations.
Partners deploy ScanSkinAI globally, with current activity across Hong Kong, Singapore, the United Kingdom and the broader Asia-Pacific region. Multi-language support and Fitzpatrick I–VI coverage make it suitable for diverse end-user populations.
Small businesses with 1–99 employees should use the self-serve checkout on the small-business pricing page. Large employers with 100+ seats should email info@ScanSkinAI.com for custom pricing, dedicated onboarding, SSO and a security review. This page is for organisations that want to embed or resell ScanSkinAI under their own brand.
Book a ScanSkinAI Partner Demo
See how AI skin cancer screening fits your insurer, telemedicine, healthcare or employer platform — through REST API, white-label widget, SSO or direct access.
Looking for a Different ScanSkinAI Solution?
This page focuses on API, white-label and SSO deployment for insurers, telemedicine and healthcare partners. If you need something different, start here.
When to seek medical help
ScanSkinAI provides AI-supported screening, not a diagnosis. Use the guidance below alongside — never instead of — professional judgement. A low-risk result does not guarantee a lesion is harmless.
Arrange a routine assessment
- A new mole appearing after age 40
- A mole that looks distinctly different from your others
- You have a personal or family history of melanoma
Seek prompt advice (within ~2 weeks)
- Change in size, shape or colour over weeks/months
- Persistent itch, crust or new bleeding
- A pigmented streak under a fingernail or toenail
See NICE NG12 on suspected-cancer referral pathways.
Seek urgent help
- A rapidly growing pigmented or pink lesion
- An ulcerating, non-healing lesion
- New swollen lymph nodes near a suspicious mole
Seek medical advice even when an AI screening result appears low risk, if a lesion is changing, bleeding, painful or personally concerning.
Medical sources and further reading
Independent sources used to support guidance on this page. Links open in a new tab.
- NHS — Moles · accessed June 2026
- NHS — Melanoma skin cancer · accessed June 2026
- NICE — Suspected cancer: recognition and referral (NG12) · accessed June 2026
- Cancer Research UK — Melanoma skin cancer survival statistics · accessed June 2026
- British Association of Dermatologists — Skin cancer information for patients · accessed June 2026
- American Academy of Dermatology — Skin cancer detection and prevention · accessed June 2026
- WHO — Skin cancers · accessed June 2026